Teva Pharmaceutical Industries Limited ( (TEVA) ) has released its Q3 earnings. Here is a breakdown of the information Teva Pharmaceutical Industries Limited presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Teva Pharmaceutical Industries Ltd. is a leading biopharmaceutical company known for its innovative medicines and robust generics business, operating globally to address diverse patient needs. In its third quarter of 2025, Teva reported a revenue of $4.5 billion, marking a 3% increase year-over-year, driven by the strong performance of its innovative brands like AUSTEDO and AJOVY. The company’s non-GAAP operating income margin rose to 28.9%, with a notable increase in revenues from its key innovative products, which grew by 33% in local currency. Teva’s strategic focus on innovation and transformation is evident in its continued investment in its pipeline, including the launch of new generics and biosimilars, and the advancement of clinical trials for new treatments. Looking ahead, Teva remains optimistic about its growth trajectory, aiming for a 30% non-GAAP operating profit margin by 2027, supported by its innovative product pipeline and cost-saving initiatives.